Where does H. LEE Moffitt Cancer Center AND Research Institute Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), H. LEE Moffitt Cancer Center AND Research Institute Inc. ranks #1,664 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

What is H. LEE Moffitt Cancer Center AND Research Institute Inc.'s Innovation Score?

H. LEE Moffitt Cancer Center AND Research Institute Inc. has an Innovation Score of 53.9 out of 100 (top 8% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is H. LEE Moffitt Cancer Center AND Research Institute Inc.'s patent grant rate increasing or decreasing?

H. LEE Moffitt Cancer Center AND Research Institute Inc.'s recent grant velocity is +26% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for H. LEE Moffitt Cancer Center AND Research Institute Inc.'s patents?

H. LEE Moffitt Cancer Center AND Research Institute Inc.'s patents average 14.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView US Corporation

H. LEE Moffitt Cancer Center AND Research Institute Inc.

Q: How many patents does H. LEE Moffitt Cancer Center AND Research Institute Inc. hold?

H. LEE Moffitt Cancer Center AND Research Institute Inc. holds 247 US utility patents granted between 2015 and 2025, spanning 34 technology areas.

Q: What technology areas does H. LEE Moffitt Cancer Center AND Research Institute Inc. focus on?

H. LEE Moffitt Cancer Center AND Research Institute Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 145 patents, ranking #122 of 7,163 assignees active in that subclass. Grants appear in 34 CPC subclasses total.

Q: How is the H. LEE Moffitt Cancer Center AND Research Institute Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 247 granted patents across 34 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, H. ranks #1,664 of 49,997 tracked US assignees by granted-patent volume, with 247 patents across 34 technology areas.

#1,664
of 49,997 US assignees by volume: Top 8%
by Innovation Score (53.9/100): 14.4
avg claims per patent: +26%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1664 · US Corporation #1,664 · 247 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-MID 247 grants
TOP-DECILE #1,664/49,997
PHOTO-FINISH Biogen MA
CPC-FOCUS A61K · 34 areas
INNOV-PAR 53.9/100
CLAIMS-RICH 14.4 claims/avg
TYPE-USCORP US Corporation
VEL-UP +26% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Biogen MA Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How H.’s 53.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 19.0 pts (35%) Velocity 5.5 pts (10%) Breadth 20.6 pts (38%) Claim depth 8.6 pts (16%)

Qualcomm Incorporated · highest

85
H LEE Moffitt… · this assignee

54
Marvell Israel (M I… · near

54
Praxis Precision… · near

54
Solo Brands · near

54
Sorin CRM SAS · near

54
3D Lighting… · lowest

7

What this shows H.'s Innovation Score is 53.9/100 (top 8% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for H.?

Each dot is one of H.’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). H.’s own 14.4 claims/patent is at or below the 17.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

H. vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where H.'s grants concentrate

H. LEE Moffitt Cancer Center AND Research Institute Inc. is a focused PatentsView assignee: 34 CPC subclasses with 58.7% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2020 (39 grants) versus a trough of 10 in 2015. By volume, H. sits between Teradata US, Inc. and Saint-gobain Ceramics & Plastics, Inc..

H.'s three-year grant acceleration

From 2019–2021 to 2022–2024, H. LEE Moffitt Cancer Center AND Research Institute Inc. moved from 89 to 74 grants (0.83x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,716. See the growth leaderboard.

Teradata US

248
Water Pik

248
Biogen MA

247
Cambridge Enterpr…

247
Honeywell Federal…

247
J Choo

247
Nice

247
Saint-gobain Cera…

247
H LEE Moffitt Can… ◀

247

What this shows H. holds 247 patents at rank #1,664, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near H

By rank, the assignees closest to #1,664 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in H's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for H, neither rank-band nor same-CPC leaders (those blocks stay above). In A61K (Preparations FOR Medical), H ranks #122 of 7,163 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (54 here).

Marvell Israel (M.I.S.L) Ltd. 54 Sorin CRM SAS 54 Solo Brands, LLC 54 Praxis Precision Medicines, Inc. 54

Similar claim depth

Nearest assignees by average claims per patent (14.4 here).

Nanjing Chervon Industry Co., Ltd. 14.4 avg Sick AG 14.4 avg Semes Co., Ltd. 14.4 avg Powertech Technology Inc. 14.4 avg

H.'s Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

H. LEE Moffitt Cancer Center AND Research Institute Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	10	4.0%
2016	15	6.1%
2017	20	8.1%
2018	23	9.3%
2019	34	13.8%
2020	39	15.8%
2021	16	6.5%
2022	27	10.9%
2023	17	6.9%
2024	30	12.1%
2025partial year	16	6.5%

Which technologies does H. LEE Moffitt Cancer Center AND Research Institute Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 145

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 100

C07K - Peptides 68

C07D - Heterocyclic Compounds 60

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 51

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 32

A61B - DIAGNOSIS; SURGERY; Identification 31

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 27

G06T - Image Data Processing OR Generation, IN General 24

C07C - Acyclic OR Carbocyclic Compounds 23

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 21

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 17

G06F - Electric Digital Data Processing 12

G06V - Image OR Video Recognition OR Understanding 9

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 9

Top 15 of 34 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

H. LEE Moffitt Cancer Center AND Research Institute Inc.'s patent record in context - here's where to go next.

H. LEE Moffitt Cancer Center AND Research Institute Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 58.7% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #1,664 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare H. LEE Moffitt Cancer Center AND Research Institute Inc. against Teradata US, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 53.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.